Tower Research Capital (TRC)’s Mangoceuticals MGRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$327 Sell
763
-20
-3% -$9 ﹤0.01% 5619
2026
Q2
$298 Sell
783
-2
-0.3% -$1 ﹤0.01% 5077
2026
Q1
$283 Sell
785
-217
-22% -$104 ﹤0.01% 4925
2025
Q4
$741 Buy
+1,002
New +$1.62K ﹤0.01% 4826
2025
Q3
– Sell
-1,850
Closed -$2.81K – 5462
2025
Q2
$2.81K Buy
1,850
+207
+13% +$388 ﹤0.01% 4591
2025
Q1
$3.2K Sell
1,643
-990
-38% -$3.56K ﹤0.01% 4452
2024
Q4
$6.37K Buy
+2,633
New +$6.9K ﹤0.01% 4180

Other funds holding MGRX

Tower Research Capital (TRC)'s MGRX Position: Q3 2026 in Review

Tower Research Capital (TRC) reduced its Mangoceuticals (MGRX) stake by 2.6% in Q3 2026, selling an estimated $9 and leaving 763 shares worth $327. The position accounts for ﹤0.01% of the portfolio, ranked #5619.

Tower Research Capital (TRC) first reported a position in MGRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.37K in Q4 2024. 19 funds tracked by Wall St. Rank hold MGRX as of Q3 2026.

  • Tower Research Capital (TRC) held 763 shares of Mangoceuticals worth $327 as of Q3 2026.
  • Tower Research Capital (TRC) sold 20 Mangoceuticals shares in Q3 2026, an estimated $9.
  • Mangoceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5619 holding.
  • Tower Research Capital (TRC) first reported a position in Mangoceuticals in Q4 2024 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s Mangoceuticals position peaked at $6.37K in Q4 2024.
  • 19 funds tracked by Wall St. Rank held Mangoceuticals as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.